Venus Mediscience Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 07-01-2025
- Paid Up Capital ₹ 2.00 M
as on 07-01-2025
- Company Age 16 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.74 M
as on 07-01-2025
- Revenue %
(FY 2017)
- Profit 9.14%
(FY 2017)
- Ebitda 73.61%
(FY 2017)
- Net Worth -67.47%
(FY 2017)
- Total Assets -0.10%
(FY 2017)
About Venus Mediscience
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 2.00 M.
The company currently has active open charges totaling ₹4.74 M.
Savita Singh and Sunil Singh serve as directors at the Company.
- CIN/LLPIN
U85120BR2008PTC013933
- Company No.
013933
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Sep 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Muzaffarpur, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Venus Mediscience Private Limited offer?
Venus Mediscience Private Limited offers a wide range of products and services, including Common Disease Medicines, Allopathic Cough Syrup, Surgical & ICU Equipments, Oxygen Flow Meter, Digestive System Drugs & Medicines, Digestive Drugs, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Antacid Drugs.
Who are the key members and board of directors at Venus Mediscience?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Savita Singh  | Director | 16-Sep-2008 | Current |
| Sunil Singh | Director | 16-Sep-2008 | Current |
Financial Performance of Venus Mediscience.
Venus Mediscience Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a slight improvement in profitability, with a 9.14% increase in profit. The company's net worth observed a substantial decline by a decrease of 67.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Venus Mediscience?
In 2017, Venus Mediscience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 28 Aug 2020 | ₹0.60 M | Open |
State Bank Of India Creation Date: 14 Nov 2011 | ₹4.14 M | Open |
How Many Employees Work at Venus Mediscience?
Unlock and access historical data on people associated with Venus Mediscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Venus Mediscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Venus Mediscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
